Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate
Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...
Costly GLP-1 drug use for wight loss has soared, study reports
The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...
Medifast: GLP-1 Caused A Vicious MLM Flywheel Effect
Medifast, Inc. faces declining demand amid GLP-1 impact, struggling repositioning efforts, and earnings uncertainty. Read ...
MedPage Today on MSN22h
GLP-1 Spending Hit $5.8 Billion in 2022 for U.S. Adults Without Diabetes
The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...
ConsumerAffairs1d
Oral Semaglutide (GLP-1) may reduce heart attack, stroke risk in diabetes patients
In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...
The Rocky Mountain Collegian6d
Liraglutide Peptide: Unveiling Its Potential Implications in Scientific Research
Liraglutide is a peptide that has gained significant attention in scientific research due to its structural similarity to ...
Stud reveals more type 1 diabetics are obese, taking GLP-1 drugs
Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.
Morningstar6d
Collective Health and Noom Partner to Offer Comprehensive Weight Management Solution and Integrated GLP-1 Program
On average, clients covering GLP-1 drugs for weight loss would have seen ... “We know that without a better cost management structure, most employers are unable to cover these life-changing ...